Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5HPZU)

Drug Name

NOX-H94 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Anemia	3A00-3A9Z	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Hepcidin (HAMP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PTG-300	DMOYS8A	Hemochromatosis	5C64.1Y	Phase 2	[2]
LJPC-401	DMVM13R	Beta thalassemia	3A50.2	Phase 2	[3]
Hepcidin mab	DMBFYSR	Anemia	3A00-3A9Z	Phase 1	[4]
LY2787106	DM9NYHT	Anemia	3A00-3A9Z	Phase 1	[5]
12B9m	DM5IUN8	Anaemia	3A90	Preclinical	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys. Blood. 2013 Mar 21;121(12):2311-5.
2	Clinical pipeline report, company report or official report of Protagonist Therapeutics.
3	ClinicalTrials.gov (NCT03395704) A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis. U.S. National Institutes of Health.
4	The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci. 2014 March; 35(3): 155-161.
5	A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. J Hematol Oncol. 2017 Mar 21;10(1):73.
6	Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. AAPS J. 2010 Dec;12(4):646-57.